A practical reference on lipolysis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-16. Anything still debated is marked as such rather than presented as settled.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
=== Biotransformation === Caffeate O-methyltransferase is an enzyme responsible for the transformation of caffeic acid into ferulic acid. Caffeic acid and related o-diphenols are rapidly oxidized by o-diphenol oxidases in tissue extracts.
=== State offices, regulations === Anti–money laundering office of the Philippines Anti-Money Laundering Office (Thailand) AMLCFT regulation in the United States US Anti–money laundering program (Patriot Act, Title III, Subtitle B Sec.352) Russian Federal Financial Monitoring Service ("Rosfinmonitoring") Australian Transaction Reports and Analysis Centre or AUSTRAC, Australian government agency, Australia's anti–money laundering and counter–terrorism financing regulator
== Adverse effects == The most common side effects include headache, fever, fall, cough, vomiting, abdominal pain, cold symptoms (nasopharyngitis) and nausea. In animal studies, no significant changes were seen in the male reproductive system of monkeys and mice following weekly subcutaneous administration. According to the reports obtained from the clinical trials, pain at the site of intravenous administration, back pain, oropharyngeal pain, sprain in ligaments, diarrhea, dizziness, contusion, flu, ear infection, rhinitis, skin abrasion, tachycardia, and constipation occurred at an elevated frequency in the treatment group, as compared to their placebo counterparts. Hypersensitivity reactions, including rash, fever, itching, hives, skin irritation (dermatitis) and skin peeling (exfoliation), have occurred in people who were treated with golodirsen. Renal toxicity was observed in animals who received golodirsen. Although renal toxicity was not observed in the clinical studies with golodirsen, potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. Renal function should be monitored in those taking golodirsen.
Team Fortress 2 is a multiplayer team-based first-person shooter that was first available as part of The Orange Box as one of its three original new games. The game is a sequel to the original Quake modification, Team Fortress, and Valve's Half-Life modification, Team Fortress Classic. Its focus is on two competing teams that attack each other in order to achieve varying objectives, including capturing control points or defending them from attack, or capturing a flag. Players can choose to play as one of nine classes in these teams, each with different strengths and weaknesses. Unlike most other Source-powered games, Team Fortress 2 features a cartoon art style and non-realistic graphics. Team Fortress 2 was very well received by critics; it was particularly praised for its unique artistic direction and graphics. In June 2011, the Steam version of Team Fortress 2 became free-to-play.
==== Trophic interactions ==== Assimilation of diet into tissue has a tissue-specific fractionation known as the trophic discrimination factor. Diet sources can be tracked through a food web via deuterium isotope profiles, though this is complicated by deuterium having two potential sources – water and food. Food more strongly impacts δD than does exchange with surrounding water, and that signal is seen across trophic levels. However, different organisms derive organic hydrogen in varying ratios of water to food: for example, in quail, 20-30% of organic hydrogen was from water and the remainder from food. The precise percentage of hydrogen from water, depended on tissue source and metabolic activity. In chironomids, 31-47% of biomass hydrogen derived from water, and in microbes as much as 100% of fatty acid hydrogen can be derived from water depending on substrate. In caterpillars, diet δD from organic matter correlates linearly with tissue δD. The same relationship does not appear to hold consistently for diet δD from water, however – water derived from either the caterpillar or its prey plant is more 2H-enriched than their organic material. Going up trophic levels from prey (plant) to predator (caterpillar) results in an isotopic enrichment. This same trend of enrichment is seen in many other animals - carnivores, omnivores, and herbivores - and seems to follow 15N relative abundances. Carnivores at the same trophic level tend to exhibit the same level of 2H enrichment.
Sources: en.wikipedia.org
The result was that on January 29, 1981, Adolfo Suárez made public on television his decision to resign from the presidency of the government and the party. He justified it with the enigmatic phrase: "I do not want the democratic system of coexistence to be, once again, a parenthesis in the life of Spain". Two days later Suárez gathered the "barons" of UCD who agreed to propose Leopoldo Calvo Sotelo as candidate for the presidency of the government. The political crisis that the country was going through worsened when it was known that ETA had assassinated José María Ryan, industrial engineer of the Lemóniz Nuclear Power Plant who had been kidnapped a few days before, and coincided with the death by torture in the Carabanchel Penitentiary Hospital of the presumed etarra José Ignacio Arregui. It also fueled the tension the signs of rejection that the kings received from representatives of Herri Batasuna when they visited the Casa De Juntas De Gernika together with the lehendakari Carlos Garaikoetxea.
The authors concluded that: platelet rich plasma may help wounds to heal quicker compared to sterile gauze; Lietofix skin repair cream may help wounds to heal by 30 days compared to iodine (which helps to reduce bacteria in the wound); but it is not clear whether hydrogel dressings (designed to keep the wound moist) reduce the time it takes wounds to heal compared with cleaning the wound with iodine. Endoscopic pilonidal treatment, which uses a small camera to guide the surgeon in removing hair, is a newer method of treatment that has minimal pain and quick healing compared to surgery. A literature review of 497 patients found that the average endoscopic operation time was 34.7 minutes, and the average healing time was 32.9 days. Failure occurred in 8% of patients, who had persistent disease or recurrence. Current European Society of Coloproctology (ESCP) guidelines (2024) state that laser-based techniques such as sinus laser-assisted closure (SiLaC/SiLaT) may be considered as a minimally invasive treatment option for selected patients with pilonidal disease, reflecting an emerging but still evolving evidence base. Several randomized controlled trials have compared SiLaC, SiLaT, or other laser ablation techniques with conventional surgical approaches such as excision, curettage, or flap procedures.
== Validation Master Plan == The Validation Master Plan is a document that describes how and when the validation program will be executed in a facility. Even though it is not mandatory, it is the document that outlines the principles involved in the qualification of a facility, defines the areas and systems to be validated and provides a written program for achieving and maintaining a qualified facility with validated processes. It is the foundation for the validation program and should include process validation, facility and utility qualification and validation, equipment qualification, cleaning and computer validation. The regulations also set out an expectation that the different parts of the production process are well defined and controlled, such that the results of that production will not substantially change over time.
The story and cast performances were positively received; Time Out magazine called it "flawed but impressive". Afterward, he starred in Rob Reiner's 2007 comedy The Bucket List opposite Jack Nicholson. The plot follows two terminally ill men on a road trip with a list of things to do before they die. The film grossed $175 million worldwide.
== Treatment == Treatment for postinflammatory hyperpigmentation may include topical agents like hydroquinone, retinoids, ascorbic acid, and azelaic acid, as well as chemical peels or laser therapy to promote skin renewal and reduce pigmentation. Sun protection is also crucial to prevent further darkening of the affected skin. In severe or recurrent cases, combination therapy of hydroquinone plus one or more additional topical agents is common. Topical medications and other non-procedural treatments are preferred over chemical peels, laser therapy, dermabrasion, and other "destructive therapies". This is because the topical treatments are often very effective in managing PIH and typically cost less, while also having lower potential for side effects or worsening of the condition. Some patients (especially those with darker skin) have been known to experience worsening of their PIH with destructive therapy, rather than improvement. The reason for this is often not known.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.